Home / Newswire


Weedstocks Newswire Feed

Weedstocks news RSS feed

GreenSpace Brands Inc. to Host Second Quarter Fiscal 2019 Results Conference Call on November 15, 2018

2018-10-16 15:00:56

TORONTO, Oct. 16, 2018 /CNW/ - GreenSpace Brands Inc. ("GreenSpace" or "the Company") (TSXV: JTR) today announced that it will hold its second quarter fiscal year 2019 conference call on Thursday, November 15, 2018 at 8:30 am (ET).

A news release announcing the Company's financial results for the six months ended September 30, 2018 will be issued on the evening of Wednesday, November 14, 2018.

The call will be hosted by Matthew von Teichman, President and Chief Executive Officer and Greg Guyatt, Chief Financial Officer.  Following management's presentation, there will be a question and answer session for analysts and investors.  To participate in the teleconference, dial (416) 764-8688 or 1 (888) 390-0546 (Toll-free).  Callers are advised to call five minutes in advance of the call.

A taped rebroadcast will be available until 11:59 pm (ET) on November 22nd, 2018. To access the rebroadcast, please dial (416) 764-8677 or 1 (888) 390-0541 and use the passcode 757664.

About GreenSpace Brands Inc.


Read more

Fire & Flower Announces Agreement to Acquire Retail Cannabis Store in North Battleford, Saskatchewan

2018-10-16 14:00:56

EDMONTON, Oct. 16, 2018 /CNW/ - Independent corporate cannabis retailer Fire & Flower is pleased to announce that it has entered into binding agreement to acquire all of the issued and outstanding shares of 10945072 Canada Inc. ("North Battleford CannabisCo").  North Battleford CannabisCo has built and received approval to operate a licensed cannabis retail shop in North Battleford, Saskatchewan. The acquisition is conditional upon North Battleford CannabisCo commencing operations as a licenced cannabis retailer and receipt of all required approvals.  North Battleford CannabisCo has received advance authorization from the Saskatchewan Gaming, Liquor and Cannabis Authority to purchase and store cannabis and expects to commence operations on October 17, 2018.

The transaction is expected to close on or about October 18, 2018, following which the shop will now operate under the Fire & Flower banner, delivering an exceptional customer experience and supplying expertly-curated Health Canada-regulated products in a bright and modern environment.

"We are pleased to select Fire & Flower as the cannabis retailer of choice to continue the historic progress we have made with our licensed cannabis retail shop," said James R. Davey, President & CEO of North Battleford CannabisCo as well as Curativa Cannabis, a division of Envirosafe Chemicals Canada. "We are confident to entrust Fire & Flower's conscious philosophy and eloquent sophistication to provide cannabis to consumers in the community of North Battleford. This divestiture will allow us the opportunity to focus on our diversification into cannabis growth and production as a licenced producer."

Like all Fire & Flower shops, the one in North Battleford will follow a robust security protocol to ensure the highest standards of safety for the community, including a two-step age verification process to prohibit purchases by minors, programs to promote road safety, and extensive community engagement.

Fire & Flower is actively developing cannabis retail stores in Alberta and Saskatchewan to commence sales on October 17, 2018 and is pursuing additional opportunities to obtain cannabis retail licenses in Ontario, British Columbia and Manitoba.


Read more

CV Sciences, Inc. Partners with the Rodale Institute on Organic and Industrial Hemp Research, Joining Patagonia and Dr. Bronner’s

2018-10-16 12:45:00

LAS VEGAS, Oct. 16, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (OCTQB: CVSI) preeminent supplier and manufacturer of industry leading hemp extract brand, PlusCBD Oil™, announces that the Company is now sponsoring Rodale Institute’s research on organic hemp farming alongside industry leaders Patagonia and Dr. Bronner’s. The Rodale Institute is the nation’s leading organic farming institution, dedicated to pioneering organic farming through research and outreach.

Since 2014, CV Sciences has pioneered the hemp industry through research and development affiliations with the University of Kentucky and Murray State University, amongst others.  The Company continues to invest and support the promising future of agricultural hemp in the United States and this partnership with the Rodale Institute demonstrates our continued commitment to expanding scientific research in hemp agriculture.

Joseph Dowling, Chief Executive Officer at CV Sciences, states, “We are thrilled to expand our robust support of hemp farming research throughout the United States to increase organic production of hemp with such a forward-thinking organization like the Rodale Institute.  We believe that hemp can play a large role in the future of agriculture and look forward to working with Rodale to further organic hemp production.”

“We appreciate the support of CV Sciences as we explore hemp’s role in soil health,” said Jeff Moyer, Executive Director of the Rodale Institute. “We know that healthy soil equals healthy food equals healthy people and a healthy planet. Having a partner like CV Sciences allows us to have a much larger impact.”

To learn more about CV Sciences’ partnership with the Rodale Institute and their dedication to the future of hemp, click here.


Read more

Maple Leaf Accepts Loan Offer from Silver Arch Capital Partners

2018-10-16 12:30:00

CALGARY, Alberta, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“Maple Leaf” or the “Company”) (NEO: MGW, OTCQX: MGWFF) has accepted a loan offer from Silver Arch Capital Partners (the “Lender”) providing for a maximum amount of $5,250,000 (the “Loan”). Proceeds from the Loan will be used for the completion of construction of real property and improvements for the Company’s cannabis cultivation facility located in Telkwa, British Columbia (the “Telkwa Facility”). The maximum initial draw of the Loan is $2,875,000. Silver Arch Capital Partners is a private lender in the commercial real estate market based in Hackensack, N.J., U.S.A. website: www.silverarchcp.com.

Collateral for the Loan consists of the real property and improvements thereon located at the Telkwa Facility. The Loan shall be evidenced by a full set of loan documentation, first mortgage or deed of trust covering the Telkwa Facility, granting the Lender a first priority security interest in the Telkwa Facility.

The interest rate for the term of the Loan shall be equal to the greater of (i) twelve percent (12%); and (ii) the sum of (a) the Wall Street Journal prime rate, plus (b) 700 basis points. The Loan term is for 18 months, interest only, and there may be two six-month extensions, upon payment of 1% of the Loan amount per extension and provided the Loan is not in default. The origination fee is three percent (3%) of the Loan amount. In the event that the Loan is not advanced or if the Company fails to close the Loan, the Company has agreed to pay the Lender a break-up fee of 1% of the Loan amount in the event the Company accepts the Loan offer and the Company fails to close the Loan with the Lender.

The Loan is expected to be advanced on or about November 9, 2018, or such other date as may be determined by the Lender. There can be no guarantee that the maximum amount of the Loan will be advanced or at all by the Lender as closing shall also be subject to complete and acceptable due diligence and customary loan documentation. Further information regarding closing of the Loan will be released in due course.

For further information regarding the Company, please visit www.mlgreenworld.com.


Read more

Relevium Announces Strategic Investment in Leading Pediatric Cannabis Company and Obtains Exclusive License for the Canadian Market

2018-10-16 12:30:00

MONTREAL, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:  “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has executed a binding letter of intent for a strategic investment into CannaKids.org for an initial 25% equity. Cannakids is a leader in the medical cannabis patient research and consumer product development for pediatric and adult applications.

Strategic Focus on Patient Data and Exclusive Formulations Cannakids’ (“CK”) patient research and product development has been centered primarily around pediatric applications, but the company services and guides patients of all ages. Counting with a database of thousands of patients, CK leverages a network of trained nursing staff, pediatric and adult dosing experts, medical doctors and leading researchers in the US and Israel. Cannakids’ formulations provide medically fragile patients with tailored products and profiles that are extremely similar to that of the actual flowers of the plant while remaining free of residual solvents and unwanted contaminants. CK’s carefully formulated products are certified Gluten-Free, Non-GMO, not tested on animals and Kosher. All products are lab tested for pesticides, residual solvents, microbiological agents, terpenes profiles and overall potency to ensure optimal quality. The company distributes its products through a growing and extensive network of licensed retail locations across California, all while working on both national and international expansion plans.

Aurelio Useche, CEO of Relevium Technologies stated, “With over four years of research, patient data and passion behind the real-life success stories with pediatric and adult patients, our investment in Cannakids is highly strategic and accretive to our shareholders.” Mr. Useche further stated, “We are proud to be business partners with Tracy Ryan (CEO) and her team of talented and passionate professionals and we look forward to a solid and mutually rewarding relationship.”

Tracy Ryan, CEO of CK Properties and Cannakids stated, “The team and I are beyond excited to partner with a group that is so focused on health & wellness and has the same mission and vision as we do here at Cannakids. In this quickly emerging market, we believe that it’s a partnership like this that will help to elevate not only our conversation around medical cannabis but allow us to more effectively access and service medically fragile patients on a much grander scale.”

The Canadian Exclusive License As part of the strategic investment, the Company has obtained the exclusive Canadian license for Cannakids, which will allow Relevium to build upon CK’s existing infrastructure and standard operating procedures to launch the brand across Canada and to expand CK’s growing patient network to support ongoing research for cancer, autism and epilepsy, amongst other specialized applications.


Read more

Radient Technologies and Grupo Natac announce JV to form Natac Solutions

2018-10-16 12:08:08

EDMONTON, Alberta and MADRID, Spain, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. ("Radient" or the “Company”) (TSX Venture: RTI), to support its ongoing health and wellness activities, is pleased to announce the formation of Natac Solutions, a 50/50 Joint Venture (the “JV”) with Grupo Natac S.L. (“Natac”).

The companies have entered into a binding letter of intent that will see a portion of Radient’s Health and Wellness Solutions business folded into the JV along with a portion of Natac’s existing business to form a global entity, named Natac Solutions, based in Madrid, Spain.  Radient and Natac share a common focus in health & wellness initiatives with complementary skills, technologies and synergies to address unmet market needs. This combination will help drive innovation and global expansion for both companies.

Natac Solutions leverages Radient’s disruptive extraction and downstream technologies and Natac’s expertise with clinically validated natural ingredients. With offices and manufacturing in North and South America, Europe, and a growing presence in Asia, the Joint Venture is ready to take advantage of global trends, and create value for our stakeholders and consumers.

“We have found a partner who is equally committed to developing products that are based on sound scientific evidence who also has the ability and desire to grow its operations globally.  Natac shares our dedication to innovation and high operating standards and we are extremely pleased to partner with them,” commented Denis Taschuk, CEO of Radient.

“We are extremely excited to partner with Radient in this joint venture.” said Antonio Delgado, CEO of Natac. “The management team that has been assembled is well respected across industries, and we know that this joint venture will be successful in generating new long-term partnerships with clients. The synergistic combination of industry talent and manufacturing expertise, supported with world class quality and science sets up the JV for immediate success.”


Read more

Statement from Tetra Bio-Pharma on the legalization of recreational cannabis

2018-10-16 12:00:22

ORLEANS, ON, Oct. 16, 2018 /CNW/ - October 17th, 2018 will be remembered as one of the most significant dates in Canadian history, in our lifetime.

While there will continue to be arguments on both sides of the debate, the Government of Canada has legislated that adults will have access to cannabis for recreational use, subject to a set of guidelines that will vary from province to province.

Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), is a Canadian company that is a global leader in the discovery and development of cannabis and cannabinoid-based pharmaceuticals and is the only company in North America to work with both Health Canada and the U.S.  Food and Drug Administration on clinical programs to produce the rigorous scientific evidence required by these regulators as well as by medical professionals and insurance companies. If successful, the investigational trials will result in the manufacture of prescription drugs containing cannabis making these medications accessible to patients and reimbursed by private and public drug plans. These products will be produced for global markets including North America, Europe, South America and the Middle East. In addition to bio-pharma Tetra will introduce commercially available natural health products

While Tetra Bio-Pharma believes that cannabis has the potential to be of therapeutic benefit, as yet there is no scientific, safety, and efficacy data to support its usage. It is for this reason that we are pursuing a pharmaceutical pathway that is compliant with regulators, to establish the necessary clinical evidence that forms the basis of drug approvals. Health Canada, the United States Food and Drug Administration, and the European Medical Authority will only approve drugs for sale in these markets once they have successfully gone through a formal drug review process.  This process, which can take anywhere between 6 months and two years, is how a drug application is reviewed by scientists in the Health Products and Food Branch (HPFB) of Health Canada as well by other international regulating bodies and as required, outside experts, to assess the safety, efficacy and quality of a drug.1  Throughout the process the well-being of patients is of paramount concern. Tetra Bio-Pharma is currently funding five Health Canada authorized clinical trials, including investigational trials for advanced cancer pain, a head to head trial comparing cannabis to fentanyl in breakthrough cancer pain, fibromyalgia, and chronic pain.

According to Dr. Guy Chamberland, Chief Executive Officer and Chief Scientific Officer of Tetra Bio-Pharma, "the millions of individuals who currently suffer from painful conditions like cancer pain and fibromyalgia, or other medical problems like insomnia, depression, anxiety may be opening themselves up to unnecessary health risks with the use of recreational cannabis. Our concern also extends to seniors, children and even pets, among the most vulnerable in our society where it may be believed that cannabis will relieve common aches and pains."


Read more

ISO-SPORT™ Products Now Available Through Two UK-based Mixed Martial Arts Companies

2018-10-16 12:00:00

The U.K.’s leading online retailers of mixed martial arts accessories now offer Iso-Sport CBD Performance Product, from Isodiol International Inc.

VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) is pleased to announce that its subsidiary, ISO-SPORT™, has reached deals with two United Kingdom-based mixed martial arts retailers to sell the CBD Performance Products. Acclaimed as being two of the U.K.’s top online sources of mixed martial arts supplies, LondonFightStore.com and Grapplestore.co.uk have officially launched sales of the products to their clients.

London Fight Store is renowned for selling world-class equipment and apparel for boxing, MMA, Muay Thai, and Brazilian Jiu-Jitsu.  London Fight Store is also proud sponsors of Cage Warriors along with Iso-Sport.

Grapplestore is the U.K.’s largest online grappling store and has been trading online for over five years.  The Company is run by dedicated Brazilian Jiu-Jitsu enthusiasts and fighters offering a wide range of GIs and accessories at great prices and fast delivery with the best customer service possible.

Graham Boylan, VP for Business Development for Iso-Sport Europe comments, “Striking a deal with Grapplestore and London Fight Store is great news for our U.K. customers and Iso-Sport.  Our biggest request to date from Iso-Sport European customers has been a need for easier availability and these two companies can fully cater to those needs.”


Read more

WeedMD to Convert Toronto-Based CannDo to its First Cannabis Education Centre

2018-10-16 11:37:28

Internationally-Renowned Cannabis Advocate & Pioneer Amy “Anonymous” Brown to Oversee Education Centre as it launches “Pop-Up Shop” on October 16-18

TORONTO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has signed an agreement for a pilot project to convert a popular Toronto-based medical cannabis centre to a WeedMD cannabis education centre (“Education Centre”). Internationally-renowned medical cannabis advocate Amy Brown, also known as Amy Anonymous, will oversee the Education Centre with a preview “Pop-up Shop” opening on October 16-18, located at 685 Yonge Street, 2nd Floor in Toronto, Ontario.

“As one of the cannabis industry’s pioneers and a staunch and knowledgeable advocate, Amy has been helping patients navigate safe cannabis use for over a decade and it’s an honour to welcome Amy, her patients and her peer group to the WeedMD family,” said Keith Merker, CEO of WeedMD. “With the onset of legalization, our industry has a long way to go in helping the general public understand cannabis strains, terpene profiles, dosing, safety, etc. and Amy’s team is an added asset to our WeedMD Education Centre pilot project. This further exemplifies our commitment to our medical patients which is strongly rooted in everything we do.“

“When I started down the path of cannabis advocacy over 10 years ago, there was a limited number of trusted and knowledgeable influencers in the space but my long-standing relationship with the crusaders that planted the first seeds at WeedMD comes full-circle today as we partner to advance the need for cannabis education,” said Amy Brown, General Manager of WeedMD’s Education Centre. “Today I’m proud to officially join the team and I know that my loyal patients will transition seamlessly to the WeedMD family who’s commitment to the medical cannabis patient will always be at the core of its value system. Its promise to provide us with consistent medical-grade supply, free shipping and the absorbing of the excise tax are further validations to our partnership and commitment.”

About the “Education Centre Pop-up Shop”


Read more

Statistics Canada issues a challenge as non-medicinal cannabis becomes legal

2018-10-16 11:00:03

OTTAWA, Oct.16, 2018 /CNW/ - Tomorrow, the use of cannabis for non-medicinal purposes will become legal in Canada. How long will health professionals, law enforcement agencies, policy makers, researchers, the media and Canadians have to wait to get accurate and timely information on the effects of this change?

That's up to Canadians, says Statistics Canada. The national statistical agency is issuing a challenge. If enough Canadians report their purchases on the StatsCannabis website, Canadians will be able to track in real time the changes in social and economic behaviour related to the legalization of cannabis.

If enough data is submitted, Statistics Canada will be able to measure such things as the difference between the illegal and legal price, the reason why some people choose to purchase illegal cannabis and the number of new consumers.  Statistics Canada has created the StatsCannabis crowdsourcing platform for people to post their information.

Since the Government tabled legislation in April to legalize cannabis, Statistics Canada has been updating the national statistical infrastructure to capture and record the economic and social activities associated with the production and use of cannabis.

An important part of this infrastructure was the launch of the StatsCannabis crowdsourcing platform where Canadians are asked to anonymously submit information pertaining to the price they paid for cannabis along with information about their consumption patterns.  As of October 1, 20,000 prices have been posted on the website.


Read more